Anyone down here
Centers for Disease Control and Prevention (CDC) demonstrated the urgency of measures to reduce smoking among young people: 27.1% of high school students in 2018 used tobacco products Tobacco product use among youth increased by 38.3% from 2017 to 2018 (due to e-cigarette use) The CDC data spotlights the dangerous role that e-cigarette use has among youth: E-cigarette use among high school students increased from 11.7% to 20.8% in one year (2017-2018) E-cigarettes are the most commonly used tobacco product by young Americans One Juul pod (Juul is the most commonly used e-tobacco brand in the United States) is equivalent to one pack of cigarettes Juul products are sold in flavors and easy-to-conceal devices that appeal to young Americans A report by the World Health Organization (WHO) highlighted evidence that the tobacco mega-industry specifically targets children and youth: Children and youth constitute one of the battlegrounds for competition for customers among tobacco companies The tobacco industry studied marketing approaches targeting children as young as five The tobacco industry investigated ways to prevent teenagers from quitting smoking Many of the largest and most successful tobacco advertising campaigns were directed at young Americans The tobacco industry investigated how to translate young Americans anxieties into tobacco use The WHO data, with statements taken directly from tobacco industry documents, provides a shocking, detailed view of the degree to which the tobacco industry continues to prey on Americas youth
Even non-daily use can lead to cravings and loss of control, particularly among adolescents and young adults
For cohort studies, we utilized the Newcastle-Ottawa Quality Assessment Scale for quantitative analysis, the Newcastle-Ottawa Scale was developed to assess the quality of nonrandomized studies with its design, content and ease of use directed to the task of incorporating the quality assessments in the interpretation of meta-analytic results (20)
JIG-O has received honoraria for lecturing, scientific advice, participation in clinical studies or writing for publications for the following (alphabetical order): Aflofarm, AstraZeneca, Boehringer, Chiesi, Esteve, Faes, Gebro, Menarini, and Pfizer
